Peter Voorhees, MD, on Sustained MRD Negativity in the Phase 2 GRIFFIN Trial

December 29, 2020
Peter Voorhees, MD

The myeloma expert discussed the importance of sustained MRD negativity for patients with multiple myeloma treated with daratumumab (Darzalex).

In an interview with CancerNetwork®, Peter Voorhees, MD, of the Levine Cancer Institute, discusses the updated results from the phase 2 GRIFFIN trial (NCT02874742) and the impact of daratumumuab (Darzalex) on sustained rates of minimal residual disease (MRD) negativity among patients with newly diagnosed multiple myeloma.

Transcription:

We also know that achievement of MRD negativity, while important, is just one snapshot in time. We recognize that sustained MRD negativity is also very important. We looked at the rates of patients achieving MRD negativity for at least 6 or 12 months in the 2 arms of the [GRIFFIN] trial, and in both instances, [the data] favor the daratumumab arm. If we’re looking at sustained MRD negativity, as defined by 6 months of duration [of MRD] or longer, 37.5% of the patients in the daratumumab arm have hit that metric relative to just under 8% for those in the control arm. If we’re looking at a more stringent definition of sustained MRD negativity of at least 12 months of duration or longer, it’s close to 30% in the daratumumab arm component compared [with] close to 3% in the control arm. With this updated analysis, we show that with continued therapy, the difference in depth of response continues to improve, really producing unprecedented rates of stringent CR [complete response] and MRD negativity for those patients assigned to the daratumumab arm.